Research and Markets (http://www.researchandmarkets.com/research/ll54rk/pharmapoint)
has announced the addition of the "PharmaPoint:
Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022"
report to their offering.
During the forecast period from 2012-2022, the growth of the UC market
will be driven largely by the entry of Johnson & Johnson's (J&J's)
Simponi and Takeda's Entyvio, which will lead to an increase in the
overall number of patients being treated with biologics in the US, 5EU,
Japan, and Canada. Another key event affecting the UC market is the
anticipated launch of biosimilars, given that the patent expiry of the
UC blockbusters, Remicade and Humira are set to expire in the US in 2018
and 2016, respectively.
There are three UC-approved biologics in Canada, which are the TNF
inhibitors, Remicade, Humira and Simponi. Remcade has the larger
potential patient pool, as it was approved for use in UC patients long
before Humira (in 2013), which was only approved for UC in 2013. It can
also be used either alone or in combination with conventional therapy.
This, together with its high annual cost of therapy, means that Remicade
experiences strong uptake in the Canadian UC market, which positions it
as the market-leading therapy.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/ll54rk/pharmapoint
[ Back To NFVZone's Homepage ]